Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text

Medicine, Endocrinology, Pharmacology +15

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease

Seung Pil Yun, Tae‐In Kam, Nikhil Panicker et al. · Nature Medicine · 2018 · 1.1K citations

Life Sciences, Neurobiology, Neuroscience +14

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Dilan Athauda, Kate Maclagan, Simon S. Skene et al. · The Lancet · 2017 · 851 citations · Full text

Medicine, Neurology, Pharmacology +12

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Brian Finan, Tao Ma, Nickki Ottaway et al. · Science Translational Medicine · 2013 · 675 citations

Medicine, Pharmacokinetics, Pharmacology +16

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Brian Finan, Bin Yang, Nickki Ottaway et al. · Nature Medicine · 2014 · 627 citations · Full text

Life Sciences, Biochemistry, Endocrinology +12